America Pouchitis Treatment Market Overview
America Pouchitis Treatment Market Size was valued at USD 0.06 Billion in 2023. The Global America Pouchitis Treatment industry is projected to grow from USD 0.13 Billion in 2024 to USD 0.27 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.23% during the forecast period (2024 - 2032).
Pouchitis is a nonspecific inflammatory condition in the ileal pouch reservoir. The condition exclusively occurs in patients with underlying ulcerative colitis (UC) and is rarely seen in patients with Familial adenomatous polyposis (FAP). Patients with UC or FAP opt for ileal pouch-anal anastomosis (IPAA) surgery as a treatment, and pouchitis appears as an outcome of this surgery in some cases. Pouch endoscopy is usually recommended by the physicians for diagnosis as the procedure yields valuable information on the severity of mucosal inflammation, CD of the pouch or cuffitis, presence or absence of concurrent backwash ileitis, and the presence or absence of structural abnormalities.
Notably, rising prevalence of Ulcerative Colitis (UC) is the key factors driving the pouchitis treatment market. According to the Centres for Disease Control and Prevention, in 2015, around 1.3% of the U.S. adults were diagnosed with inflammatory bowel disease (IBD). The prevalence of ulcerative colitis is reported to be 37 to 246 cases per 100,000 individuals whereas, the incidence rate is found to be 2.2 to 14.3 cases per 100,000 people.
Increasing need for ileal pouch-anal anastomosis procedure, long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), and rising geriatric population are fuelling the market growth.
According to the American Society of Colon and Rectal Surgeons, chronological age should not be an exclusion criterion for ileal pouch-anal anastomosis surgery. Patients with IBD are mostly recommended to opt IPAA surgery for the treatment. Around 89% of elderly ulcerative colitis patients undergo this surgery, suggested by the World Journal of Gastrointestinal Pharmacology and Therapeutics in 2016.
However, the side effects of the available treatment options and stringent FDA regulations may hinder the growth of the pouchitis treatment market over the forecast period. Till now not even a single drug is approved by the FDA for the treatment of pouchitis. However, few are in clinical trials waiting for approval such as Alicaforsen by Atlantic Healthcare plc
Intended Audience
- Hospitals & Clinics
- Diagnostic Centers
- Research and Development (R&D) Companies
- Government Research Institute
- Academic Institutes and Universities
Figure: America Pouchitis Treatment Market by Treatment Market Share, 2016 (%) 
Sources: Annual reports, Press release, White paper, Company presentation
America pouchitis treatment market Segment Insights
The America pouchitis treatment market is segmented on the basis of treatment and end user.
America pouchitis treatment Insights
On the basis of the treatment, the America pouchitis treatment market is segmented into antibiotics, probiotics, and others. The antibiotic segment is further sub-segmented into ciprofloxacin, metronidazole, rifaximin, and others.
America pouchitis treatment End-User Insights
On the basis of the end -users, the pouchitis treatment market is segmented into hospitals & clinics, research institutes, and others.
Key Findings
- The America pouchitis treatment market is expected to reach USD 18.8 million by 2023 at a CAGR of 8.34%.
- On the basis of the treatment, the antibiotics segment commanded the largest market share of 91.2% and is also expected to grow at a healthy CAGR of 8.65% during the forecast period 2017 to 2023.
- On the basis of the end user, the hospitals & clinics segment commanded the largest market share of 67.3% in 2016, and this segment is also expected to grow at a healthy CAGR of 8.54% during the forecast period, 2017 to 2023.
- North America holds the largest share of the Americas pouchitis treatment market and is expected to reach USD 15.06 million by 2023
America pouchitis treatment market Regional Insights
On the basis of region, the America pouchitis treatment market is segmented into North America, and South America. North America accounts for a major share owing to the rising cases of pouchitis, and high healthcare expenditure. People in this region are more inclined towards quality healthcare that leads to increase in the healthcare spending. Due to rising prevalence of pouchitis, various companies, private organizations, and government associations are also actively participating to improve the treatment options.
The Americas pouchitis market is driven by ongoing extensive research in the inflammatory bowel disease (IBD). The American Gastroenterological Association (AGA) has introduced several new research grants to support investigators studying inflammatory bowel disease (IBD) such as Takeda Pharmaceuticals research scholar awards in IBD, and Pfizer pilot research award in IBD.
Around 30% of patients with ulcerative colitis (UC) undergo colectomy with ileal pouch-anal anastomosis (IPAA) surgery and up to 50% of patients develop at least one episode of pouchitis. So, rising prevalence of ulcerative colitis is boosting the Americas pouchitis treatment market. According to the Centres for Disease Control and Prevention, in 2015, around 1.3% of the U.S. adults were diagnosed with inflammatory bowel disease (IBD). The prevalence of ulcerative colitis is reported to be 37 to 246 cases per 100,000 individuals whereas, the incidence rate is found to be 2.2 to 14.3 cases per 100,000 person-years.
America Pouchitis Treatment Market Key Players
Some of key the players in the pouchitis treatment market are
- Pfizer
- Abbott
- Allergan Plc
- Bayer
- Takeda Pharmaceutical Company Limited
- Alfa sigma
- Atlantic Healthcare
- Tillotts Pharma AG
- AstraZeneca
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- B. Braun Medical Inc.
- Valeant Pharmaceuticals
- Sucampo Pharmaceuticals
- Ironwood Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- Synergy Pharmaceuticals, Inc.
- Ardelyx, Inc.
- Sebela Pharmaceuticals
- Probi
|
Report Attribute/Metric
|
Details
|
|
Market Size
|
2032: USD 0.27 Billion
|
|
CAGR
|
5.23% (2024-2032)
|
|
Base Year
|
2023
|
|
Forecast Period
|
2024-2032
|
|
Historical Data
|
2022
|
|
Forecast Units
|
Value (USD Billion)
|
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
|
Segments Covered
|
Treatment and End-user
|
|
Geographies Covered
|
North America, Europe, Asia-Pacific, and Rest of the World (RoW)
|
|
Key Vendors
|
Pfizer, Abbott, Allergan Plc, Bayer, Takeda Pharmaceutical Company Limited, Alfa sigma, Atlantic Healthcare, Tillotts Pharma AG, AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, B. Braun Medical Inc., Valeant Pharmaceuticals, Sucampo Pharmaceuticals, Ironwood Pharmaceuticals, Inc., Astellas Pharma Inc., Synergy Pharmaceuticals, Inc., Ardelyx, Inc., Sebela Pharmaceuticals, Probi,
|
|
Key Market Opportunities
|
Rising prevalence of Ulcerative Colitis (UC)
|
|
Key Market Drivers
|
Rising geriatric population are fuelling the market growth.
|
America Pouchitis Treatment Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
